Crispr Therapeutics AG (NASDAQ:CRSP) Given Consensus Rating of “Buy” by Brokerages
Crispr Therapeutics AG (NASDAQ:CRSP) has been given a consensus recommendation of “Hold” by the sixteen research firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $57.50.
CRSP has been the topic of several research analyst reports. Barclays increased their price target on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. BidaskClub cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 11th. Canaccord Genuity initiated coverage on shares of Crispr Therapeutics in a research report on Friday, July 26th. They set a “buy” rating and a $72.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $62.00 price target on shares of Crispr Therapeutics in a research report on Wednesday, July 31st. Finally, Roth Capital increased their price target on shares of Crispr Therapeutics from $50.00 to $65.00 in a research report on Tuesday, July 30th.
Shares of CRSP stock traded up $2.14 during trading hours on Wednesday, hitting $40.05. 771,655 shares of the company were exchanged, compared to its average volume of 607,097. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.96 and a current ratio of 13.96. Crispr Therapeutics has a one year low of $22.22 and a one year high of $53.90. The business’s 50-day simple moving average is $43.30 and its two-hundred day simple moving average is $43.33. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -11.64 and a beta of 3.11.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Benjamin Edwards Inc. raised its stake in Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the period. NEXT Financial Group Inc raised its stake in Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the period. US Bancorp DE raised its stake in Crispr Therapeutics by 553.7% during the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares during the period. Coastal Investment Advisors Inc. acquired a new stake in Crispr Therapeutics during the third quarter worth about $26,000. Finally, BSW Wealth Partners acquired a new stake in Crispr Therapeutics during the second quarter worth about $39,000. Hedge funds and other institutional investors own 50.23% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What is a Derivative?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.